Nursing Medication List 2

Published on January 2017 | Categories: Documents | Downloads: 98 | Comments: 0 | Views: 264
of 22
Download PDF   Embed   Report

Comments

Content

Medications: only need the meds YOU give during your shift. Include PRNs and designate as such. Drug: astreonam: Azactam Classification: Antibiotic monobactams

Mechanism of action: !inds to bacterial cell "all membrane causing cell death# bactericidal action. Why is THIS pt taking?: U$I infection lo"er res%iratory infection se%ticemia s&in structure infections cause by '( bacteria )*.coli +. %neumoniae, Monitoring parameters: -onitor for s.s of ana%hyla/is monitor bo"el function assess res%iratory status obtain s%ecimen for culture 0 sensitivity assess for infection )vital signs urine a%%earance, Pt teaching side effects: may cause 1N2 seizures N.3 rash diarrhea dizziness headache blurred vision and redness.discomfort.%ain.s"elling at in4ection site. Drug: clindamycin: 1leocin Classification: antibiotic

Mechanism of action: !actericidal or bacteriostatic Why is THIS pt taking?: !acterial '( infection Monitoring parameters: -onitor bo"el elimination diarrhea fever abdominal cram%ing and bloody stools monitor 1!1. Pt teaching side effects: Instruct %atient to ta&e medication around the cloc& at evenly s%aced times and to

finish the drug com%letely as directed even if feeling better. Notify 51P immediately if 'I issues occur.
6izziness headache vertigo arrhythmias hy%otension NI3# %hlebitis at I3 site Pseudomembranous colitis resulting in diarrhea and bacterial gro"th of 1. difficile during treatment or "ee&s to months after treatment has sto%%ed,. Drug: 5e%arin )5e%(7oc&, Classification: anticoagulants antithrombotic

Mechanism of action: Prevention of thrombus formation and e/tension of e/isting thrombi Why is THIS pt taking?: Pro%hyla/is and treatment of venous and %eri%heral arterial thromboembolism Monitoring parameters: Assess for signs of bleeding and hemorrhage )bleeding gums# nosebleed# unusual bruising# blac& tatty stools# hematuria# fall in hematocrit or !P# guaiac %ositive stools,. -onitor for %atient for hy%ersensitivity reactions )chills fever urticarial,. -ay cause hy%er&alemia and 8 A2$ and A7$ levels# monitor for Platelet

count.
Pt teaching side effects: Advise %atient to re%ort any sym%toms of unusual bleeding or bruising to health

care A2AP. Instruct %atient not to ta&e medications containing as%irin or N2AI6s "hile on he%arin thera%y. *ffect: !leeding he%arin(induced thrombocyto%enia )5I$, )"ith or "ithout thrombosis, anemia %ain in
in4ection site osteo%orosis )long term, and fever hy%ersensitivity. Drug: acetamino%hen9$ylenol Classification: Non(o%ioid analgesic anti%yretics

Mechanism of action: Inhibits the synthesis of %rostaglandins that may serve as mediators of %ain and fever %rimary in the 1N2. It has no significant anti(inflammatory %ro%erties or 'I to/icity. Why is THIS pt taking?: Pain and fever Monitoring parameters: Assess liver function# assess %ain ty%e location and intensity %rior to and after :;(<; min follo"ing administration. Assess fever# note %resence of signs )dia%horesis tachycardia and malaise,.

Pt teaching side effects: Advise %atient to ta&e medication as directed and to avoid alcohol or avoid ta&ing it concurrently "ith salicylates or other N2AI62 for more than a fe" days. 2ide effects: an/iety headache fatigue insomnia s&in rash anemia %ancyto%enia ne%hroto/ic he%ato/icity )if overdose# antidote is acetyl cysteine )Acetadote,. Patients "ith diabetes that acetamino%hen may alter results of blood glucose

monitoring.agitation an/iety headache fatigue insomnia atelectasis dys%nea hy%er.hy%otension he%atoto/icity consti%ation.

Drug: meto%rolol9 7o%ressor

Classification: antianginals antihy%ertensive beta bloc&ers

Mechanism of action: !loc&s stimulation of beta= )myocardial,(adrenergic rece%tors. It decreased !P and heart rate# decreased fre>uency of attac&s of angina %ectoris. Why is THIS pt taking?: to decrease his cardiac "or&load )!P.5R, and %revention of -I. Monitoring parameters: : Instruct %atient to ta&e medication as directed# Assess and monitor !P# *1' and %ulse fre>uency during dose ad4ustment and %eriodically during thera%y. -onitor 3ital signs and *1' every ?(=? min during and for several hours after %arenteral administration. 5old if heart rate is less than <; b%m# systole less than =;; if cardiac out%ut is also decreased administer atro%ine ;.@?(;.? mg I3. -onitor I.O rations and daily "eights. Assess s.s of 5A )dys%nea rales.crac&les "eight gain %eri%heral edema 4ugular venous distention,. Pt teaching side effects: 1hange %ositions slo"ly to minimize orthostatic hy%otension may cause dizziness. Additional interventions for hy%ertension )lo" salt "eight loss etc., 1N2 fatigue "ea&ness an/iety de%ression dizziness dro"siness insomnia memory loss mental status changes nervousness nightmares blurred vision stuffy nose bronchos%asm "heezing bradycardia 5A %ulmonary edema hy%otension %eri%heral vasoconstriction consti%ation diarrhea N.3 hy%erglycemia hy%oglycemia bac& %ain 4oin %ain drug( induced lu%us syndrome. Drug: -or%hine Classification: o%ioid(analgesic and agonist

Mechanism of action: !inds to o%iate rece%tors in the 1N2. Alters the %erce%tion of and res%onse to %ainful stimuli "hile %roducing generalized 1N2 de%ression. Why is THIS pt taking?: Aor severe %ain# %ain associated "ith -I. Monitoring parameters: Assess and monitor res%iration 7O1 !P *1' and Pulse! Assess ty%e location intensity of %ain %rior to and @; min follo"ing I3 administration. Pt teaching side effects: Confusion sedation res%iratory de%ression hy%otension bradycardia consti%ation N.3 urinary retention flushing itching s"eating %hysical %sychological de%endency tolerance. Drug: Ondansetron9 Bofran Classification: Anti(emetics ?(5$: antagonist

Mechanism of action: !loc&s the effects of serotonin at ?(5$:(rece%tor sites located in vagal nerve terminals and the chemorece%tor trigger zone in the 1N2# decreased incidence and severity of N.3. Why is THIS pt taking?: Prevention of nausea and vomiting Monitoring parameters: Assess %atient for N.3 abdominal distension and bo"el sounds %rior to and follo"ing administration# monitor *1' in %atients "ith hy%o&alemia or hy%omagnesemia bradyarrhythmias or %atients ta&ing concomitant medications that %rolong the C$ interval. Pt teaching side effects: 5eadache dizziness dro"siness fatigue "ea&ness C$ interval %rolongation $orsade de Pointes 'I consti%ation diarrhea and abdominal %ain.

Drug: %olyethylene glycol ) 'lycola/

-irala/,

Classification: osmotic la/ative

Mechanism of action: Polyethylene glycol )P*', in solution. Acts as an osmotic agent dra"ing "ater into the lumen of the 'I tract# evacuation of the 'I tract "ithout "ater or electrolyte imbalance. Why is THIS pt taking?: $reatment of occasional consti%ation Monitoring parameters: Assess %atient for abdominal distention %resence of bo"el sounds and usual %attern of bo"el function# assess color consistency and amount of stool %roduced. 5old if diarrhea! Pt teaching side effects: Notify healthcare %rovider for the follo"ing adverse effects: urticarial abdominal

bloating cram%ing flatulence and nausea. Drug: docusate sodium )1olace 1orrectol 2ilace, Mechanism of action: 2oftening and %assage of stool. Why is THIS pt taking?: 1onsti%ation Monitoring parameters: Inform %atient that @(D days may be re>uired to %roduce a bo"el movement# Assess for abdominal distention %resence of bo"el sounds and usual %attern of bo"el function. Assess color consistency and amount of stool %roduced. Pt teaching side effects: Advise %atients that la/atives should be used only for short(term thera%y. *ncourage %atients to use other forms of bo"el regulation such as increasing bul& in diet. Advise %atient not to use la/atives "hen abdominal %ain nausea vomiting or fever is %resent. Advise %atient not to ta&e medication "ithin @hrsofother la/atives. Notify healthcare %rovider of the follo"ing adverse effects: throat irritation mild cram%s diarrhea and rashes.
Drug: Bol%idem9 Ambien Classification: sedative.hy%notics

Classification: la/atives .stool softeners

Mechanism of action: Produces 1N2 de%ression by binding to 'A!A rece%tors# sedation and induction of slee%. Why is THIS pt taking?: Insomnia Monitoring parameters: Assess mental status slee% %atterns and %otential for abuse %rior to administration. Assess %atient for %ain alertness at time of %ea& effect notify %rovider if desired sedation does not occur. Pt teaching side effects: 6aytime dro"siness dizziness abnormal thin&ing amnesia behavior changes EdruggedF feeling hallucinations N.3 ana%hylactic reactions hy%ersensitivity reactions and tolerance. Drug: 5ydrocortisone91ortef Classification: antiasthmatics# corticosteroids )systemic,

Mechanism of action: 2u%%ress inflammation and the normal immune res%onse# su%%ress adrenal function at chronic doses. Why is THIS pt taking?: -anagement of adrenocortical insufficiency.su%%ression of inflammation and modification of the normal immune res%onse. Monitoring parameters: Assess for signs of adrenal insufficiency )hy%otension "eight loss "ea&ness n.v anore/ia lethargy confusion restlessness, before and %eriodically during thera%y. -onitor I.O ratios and daily "t. Observe %atient for %eri%heral edema rales.crac&les or dys%nea. Assess sym%toms of ulcerative colitis guaiac(test stools# su%%ress reactions to allergy s&in test. Pt teaching side effects: 6e%ression eu%horia headache %ersonality changes restlessness cataracts %e%tic

ulceration anore/ia n.v decrease "ound healing ecchymosis fragility adrenal su%%ression fluid retention hy%o&alemia hy%o&alemic al&alosis thromboembolism increase susce%tibility to infection.

Drug: "spirin

other: #cotrin Classification: $hera%eutic: anti%yretics non(o%ioid analgesics Pharmacologic: salicylates

Mechanism of action: Irreversibly inhibits cycloo/ygenase(= and @ )1OG(= and @, enzymes via acetylation "hich results in decreased formation of %rostaglandin %recursors# irreversibly inhibits formation of %rostaglandin derivative thrombo/ane A@ via acetylation of %latelet cycloo/ygenase thus inhibiting %latelet aggregation. Why is THIS pt taking?: Pro%hyla/is to %revent recurrence of his myocardial infarction also reduces his blood clotting )thrombi formation,. Monitoring parameters: -onitor for s.s of 'I u%set and bleeding.bruising liver A/. Pt teaching side effects: Instruct %atient to ta&e "ith a full glass of "ater and in u%right %osition )if %ossible, for =?(:; minutes after administration. 7imit alcohol use to decrease gastric irritation. Advise health care %rofessionals of medication use %rior to surgery. 2ide *ffects: hearing loss tinnitus 'I bleeding dys%e%sia e%igastric distress heartburn nausea increased bleeding time. Drug: 7asi/ )furosemide, Classification: thera%eutic: diuretics %harmacologic: loo% diuretics

Mechanism of action: Inhibits the reabsor%tion of sodium and chloride from the loo% of 5enle and distal renal tubule. Increases renal e/cretion of "ater sodium chloride magnesium %otassium and calcium. Why is THIS pt taking?: Increase urine out%ut )diuresis, "hile ridding the body of e/cess fluid to decrease his cardiac "or&load. Monitoring parameters: Assess fluid status during thera%y )daily "eight I.O amount and location of edema lung sounds s&in turgor mucous membranes. Assess elderly for fall ris&. Assess for tinnitus and hearing loss. -onitor electrolytes renal and he%atic function serum glucose and uric acid. -onitor serum %otassium calcium magnesium !UN serum glucose creatinine and uric acid levels. Pt teaching side effects: Instruct %atient to ta&e as directed. 1onsult health care %rofessional regarding a diet high in %otassium. 1hange %ositions slo"ly to minimize orthostatic hy%otension may cause dizziness. 2ide *ffects ( fluid and electrolytes: dehydration hy%ochloremia hy%o&alemia hy%omagnesemia hy%onatremia hy%ovolemia metabolic al&alosis# life threatening: 2tevens(Hohnson syndrome to/ic e%idermal necrolysis a%lastic anemia agranulocytosis. Drug: lisino%ril )Bestril, Classification: thera%eutic: antihy%ertensive %harmacologic: A1*(Inhibitor Mechanism of action: !loc&s the formation of angiotensin II and inhibits the brea&do"n of brady&inin )vasodilator,. $he anti(hy%ertensive action of A1* inhibitors is %rimarily caused by a reduction in %ulmonary vascular resistance )P3R, decreasing both arterial and venous %ressure. !y reducing angiotensin(stimulated aldosterone secretion A1* inhibitors %revent the com%ensatory increase in NaI retention and %lasma volume seen "ith other agents. In %atients treated "ith A1* inhibitors renal NaI retention is decreased "hereas renal +I retention is increased. Why is THIS pt taking?: A1*(I vasodilation decreases his cardiac "or&load# lo"ers !P and treats 15A Monitoring parameters: -onitor !P %ulse "eight edema lung sounds )rales crac&les, dys%nea

A2$.A7$ increases H36. -onitor !UN and creatinine for renal function and electrolyte levels %eriodically. 2erum %otassium !UN and creatinine may be 8 "hereas sodium levels may be J. Pt teaching side effects: 1hange %osition slo"ly avoid O$1 cough meds that can raise blood %ressure additional interventions for hy%ertension )lo" salt e/ercise."eight loss no smo&ing lo" stress, monitor !P %eriodically. 2ide effects: the most common side effect of A1* inhibitors is a dry non%roductive cough )@;K of %atients, caused by increased brady&inin levels. 1ause fetal and neonatal morbidity and mortality "hen administered to %regnant "omen. Rash first dose hy%otension cough hy%er&alemia renal failure dizzy fatigue headache. Drug: magnesium chloride )-A' delay, Classification: mineral and electrolyte re%lacements.su%%lements Mechanism of action: *ssential for the activity of many enzymes# im%ortant role in neurotransmission and muscular e/citability. Why is THIS pt taking?: $o treat or %revent hy%omagnesemia# treats hy%otension and consti%ation. Monitoring parameters: 3ital signs and labs Pt teaching side effects: 6o not crush %ill it is time released. 1onsult %rescriber before using magnesium if heLs ta&ing other drugs. -agnesium may delay or enhance absor%tion of other drugs. 2ide effects: Abru%t elevation of %lasma -g can remove the stimulus for -g retention and lead to increased e/cretion# 6iarrhea# 6rug interactions# -agnesium into/ication Aluminum into/ication. Drug: %i%eracillin.tazobactam )Bosyn, Classification: anti(infectives 0 e/tended s%ectrum %enicillins

Mechanism of action: Pi%eracillin: !inds to bacterial cell "all membrane causing cell death. 2%ectrum is e/tended com%ared "ith other %enicillins. $azobactam: Inhibits beta(lactamase an enzyme that can destroy %enicillins. Why is THIS pt taking?: -anagement of sus%ected %neumonia. Monitoring parameters: Assess %atient for infection at beginning of and during thera%y )vital signs,. Obtain a history before initiating thera%y to determine %revious use of and reactions to %enicillins or ce%halos%orins. Observe %atient for signs and sym%toms of ana%hyla/is )rash %ruritus laryngeal edema "heezing,. *valuate renal and he%atic function 1!1 serum %otassium and bleeding times %rior to and routinely during thera%y. Pt teaching side effects: Advise %atient to re%ort signs of su%erinfection )blac& furry overgro"th on tongue vaginal itching or discharge loose or foul(smelling stools, and allergy. 1aution %atient to notify health care %rofessional if fever and diarrhea occur es%ecially if stool contains blood %us or mucus. Advise %atient not to treat diarrhea "ithout consulting health care %rofessional. -ay occur u% to several "ee&s after discontinuation of medication. 2ide effects: diarrhea rashes %ain and %hlebitis at I3 site M life threatening: %seudomembranous colitis seizures ana%hyla/is and serum sic&ness. Drug: %regabalin )7yrica, stabilizer Classification: thera%eutic: analgestic anticonvulsant mood Pharmacologic: 'A!A analogues non(o%ioid analgesic Mechanism of action: !inds to calcium channels in 1N2 tissues "hich regulate neurotransmitter release. 6oes not bind to o%ioid rece%tors. $hera%eutic *ffects: 6ecreased neuro%athic or %ost(her%etic

%ain. 6ecreased %artial(onset seizures. Why is THIS pt taking?: 5e is ta&ing this for %ain management. Monitoring parameters: -onitor for and %rom%tly re%ort mental status or behavior changes. -onitor for "eight gain %er%heral edema and 2.2 of heart failure es%ecially ". concurrent thiazolidinedione thera%y. -onitor baseline and %eriodic &idney f/n tests# %eriodic %latelet counts. -onitor diabetics for increased incidences of hy%oglycemia. 2u%ervise ambulation es%ecially "hen other 1N2 drugs are used concurrently. Pt teaching side effects: 6o not discontinue abru%tly# may cause insomnia nausea headache or diarrhea. -ay cause dizziness dro"siness and blurred vision. Avoid driving or activities re>uiring alertness until res%onse to medication is &no"n. Notify health care %rofessional if changes in vision occur. Prom%tly re%ort une/%lained muscle %ain tenderness or "ea&ness es%ecially if accom%anied by malaise or fever. Notify health care %rofessional if thoughts about suicide or other unusual changes in behavior or mood occur. -ay cause edema and "eight gain. Avoid alcohol or other 1N2 de%ressants. Notify health care %rofessional of medication regimen before treatment or surgery. 1arry identification describing disease %rocess and medication regimen at all times. 2ide effects: 2UI1I6A7 $5OU'5$2 dizziness dro"siness im%aired attention.concentration.thin&ing# edema# blurred vision# dry mouth abdominal %ain consti%ation 8 a%%etite vomiting# thrombocyto%enia# "eight gain# allergic reactions fever. Drug: sertraline $%oloft& )22RIs, Classification: antide%ressants# selective serotonin reu%ta&e inhibitors

Mechanism of action: Inhibits neuronal u%ta&e of serotonin in the 1N2 thus %otentiating the activity of serotonin. 5as little effect on nore%ine%hrine or do%amine. $hera%eutic *ffects: Antide%ressant action. 6ecreased incidence of %anic attac&s. 6ecreased obsessive and com%ulsive behavior. 6ecreased feelings of intense fear hel%lessness or horror. 6ecreased social an/iety. 6ecrease in %remenstrual dys%horia. Why is THIS pt taking?: 6e%ression Monitoring parameters: -onitor mood suicidal tendencies a%%etite nutritional inta&e "ee&ly "eights fre> of O16 behaviors fre> of %anic attac&s sym%toms of fear hel%lessness 0 horror blushing s"eating trembling tachycardia during social interactions feeling angry tense tired crying easily sad or ho%eless arguing for no reason. Pt teaching side effects: $he drug "ill achieve ma/imum effectiveness after several "ee&s of thera%y. 6o not abru%tly sto% medication. Notify health care %rofessional immediately if you have thoughts about suicide. 2ide effects: dizziness dro"siness fatigue headache insomnia diarrhea dry mouth nausea se/ual dysfunction increased s"eating tremor# life threatening: N*URO7*P$I1 -A7I'NAN$ 2YN6RO-* 2UI1I6A7 $5OU'5$2 2*RO$ONIN 2YN6RO-*. Drug: %otassium chloride )+lor(1on, Classification: $hera%eutic: mineral and electrolyte re%lacement.su%%lement

Mechanism of action: -aintain acid(base balance isotonicity and electro%hysiologic balance of the cell. *ssential to transmission of nerve im%ulses# contraction of cardiac s&eletal and smooth muscle# gastric secretion# renal function# tissue synthesis# and carb metabolism. Why is THIS pt taking?: 5e is ta&ing this because his %otassium lab results "ere lo".

Monitoring parameters: -onitor for 2.2 of hy%o&alemia )"ea&ness fatigue arrhythmias %olyuria %olydi%sia, and hy%er&alemia. -onitor %ulse !P and *1'. 7abs: %otassium before and during. Renal function bicarbonate and %5. -agnesium levels and chloride levels. -onitor for to/icity and overdose )slo" irregular heart rate fatigue muscle "ea&ness,. Pt teaching side effects: $a&e as directed es%ecially "hen concurrent digo/in or diuretics are ta&en. A missed dose should be ta&en as soon as remembered "ithin @ hr# if not return to regular dose schedule. 6o not double dose. 'I irritation or ulceration may result from che"ing enteric(coated tablets or insufficient dilution of li>uid or %o"der forms. Avoid salt substitutes or lo"(salt mil& or food unless a%%roved by health care %rofessional. Read all labels to %revent e/cess %otassium inta&e. $each %otassium food sources. 1om%ly "ith recommended diet. Re%ort dar& tarry or bloody stools# "ea&ness# unusual fatigue# or tingling of e/tremities. Notify health care %rofessional if nausea vomiting diarrhea or stomach discomfort %ersists. Regular follo"(u% e/ams are im%ortant to monitor serum levels and %rogress. 2ide effects: confusion restlessness "ea&ness ab %ain diarrhea gas n.v# life threatening: ARR5Y$5-IA2.

6rug: Albuterol 2ulfate: Proventil 5AA inhaler

1lassification: !ronchodilator adrenergic

-echanism of action: !inds to beta@(adrenergic rece%tors# bronchodilator that rela/es muscles in the air"ays and increases air flo" to the lungs. Nhy is $5I2 %t ta&ingO: Nheezing -onitoring %arameters: Assess lung sounds %ulse and !P before administering and during %ea& of medication. Note amount color and character of s%utum %roduced# monitor %ulmonary function tests before initiating thera%y and %eriodically# observe for %arado/ical bronchos%asm )"heezing, Pt teaching.side effects: Instruct %atient to ta&e albuterol doses as directed not double doses or increase fre>uency of doses. Advise %atient to rinse mouth "ith "ater after each use to minimize dry mouth and clean mouth%iece "ith "ater at least once a "ee&. 2ide effects: Nervousness restlessness headache insomnia Nheezing chest %ain %al%itations angina arrhythmias hy%ertension n.v hy%erglycemia hy%o&alemia and tremors.
Drug: diltia'em Cardi'em $other Dilacor( Tia'ac& Classification: antianginals( anti(arrhythmic antihy%ertensive Pharmacologic: calcium channel bloc&ers
Mechanism of action: systemic vasodilation resulting in decreased !P. 1oronary vasodilation resulting in

decreased fre>uency and severity of attac&s of angina# Reduction of ventricular rate in atrial fibrillation or flutter. Why is THIS pt taking? 5y%ertension Angina and A(Aib Monitoring parameters: -onitor !P and %ulse %rior to thera%y and %eriodically# -onitor *1' %eriodically# may cause %rolonged PR interval. -onitor I.O ratios and daily "eight. Assess for signs of 5A )%eri%heral edema rales.crac&les dys%nea "t. gain 4ugular venous distention,. Assess for rash %eriodically during thera%y# 6iscontinue if severe or accom%anied "ith fever general malaise fatigue oral lesions blisters he%atitis and.or eosino%hilia. Pt teaching side effects: Advise %atient to ta&e medication as directed at same time each day even if

feeling "ell do not double doses discontinued gradually avoid large amounts of gra%efruit 4uice.day during thera%y and monitor %ulse change %ositions slo"ly to minimize orthostatic hy%otension avoid alcohol O$1 med vitamins or herbal %roducts. Side #ffects: %eri%heral edema bradycardia chest %ain hy%otension %al%itations synco%e tachycardia increase liver enzymes anore/ia consti%ation diarrhea dry mouth dys%e%sia N.3 dysuria nocturia %olyuria 2tevens(Hohnsons syndrome dermatitis flushing s"eating rash hy%erglycemia "eight gain muscle cram%s %aresthesia tremor gingival hy%er%lasia.

6rug: 5ydrocodone.Acetamino%hen )Norco 7ortab Bydone., analgesics

1lassification: O%ioid

-echanism of action: 6ecrease in severity of moderate %ain 0 su%%ression of the cough refle/ Nhy is $5I2 %t ta&ingO Pain management -onitoring %arameters: Assess ty%e location and intensity of %ain %rior to and = hr. after administration. Assess !P %ulse and res%irations before and %eriodically during administration. Assess level of sedation. -onitor for he%atic to/icity liver function. Pt teaching.side effects: Advise %atient to ta&e medications as directed and not to ta&e more than the recommended amount. 2evere and %ermanent liver damage may result from %rolonged use or high doses of acetamino%hen or ibu%rofen. Advise %atient to change %ositions slo"ly to minimize orthostatic hy%otension. -ay cause dro"siness or dizziness call for assistance "hen ambulating 0 &ee% good oral hygiene. 2ide *ffects: confusion dizziness sedation eu%horia hallucinations headache res%iratory de%ression hy%otension bradycardia consti%ation dys%e%sia nausea vomiting 0 tolerance.
Drug: losartan )1ozaar, Classification: Antihy%ertensive) angiotensin rece%tor bloc&ers

)AR!s,
Mechanism of action: !loc&s vasoconstrictor and aldosterone(%roducing effects of angiotensin II at

rece%tor sites including vascular smooth muscle and adrenal glands. $hera%eutic: 7o"ers !P. 2lo"ed %rogression of diabetic ne%hro%athy. 6ecreased ris& of stro&e in %atients "ith hy%ertension and left ventricular hy%ertro%hy. Why is THIS pt taking? Aor hy%ertension to %revent stro&e and left ventricular hy%ertro%hy Monitoring parameters: -onitor %otassium )hy%er&alemia, !UN and serum creatinine may be elevated. assess for signs of angioedema )dys%nea facial s"elling, rarely though monitor daily "eight and resolution of fluid overload )crac&les dys%nea 4ugular venous distention,# may cause increase uric acid slight decrease in hemoglobin and hematocrit neutro%enia and thrombocyto%enia. -onitor renal function and electrolyte levels %eriodically. Pt teaching side effects: instruct %atient to notify %rovider if s"elling of face eyes li%s or tongue occurs or difficulty s"allo"ing or breathing. Instruct %atient and family on %ro%er techni>ue for monitoring !P. Advise them to chec& !P at least "ee&ly and to re%ort significant changes. 1aution %atient to avoid sudden changes in %osition to decrease orthostatic hy%otension# may cause dizziness no driving avoid

salt substitutes containing %otassium or sodium in high >uantities unless directed by %hysician. Narn %atient not to discontinue thera%y unless directed encourage %atient to com%ly "ith additional interventions for hy%ertension )"t. reduction lo" sodium diet 6.1 smo&ing or alcohol use regular e/ercise stress management,. Re%ort any O$1 %roducts being ta&en es%ecially cough cold or allergy remedies. Drug: montelukast $Singulair& P*+ Classification: Allergy cold 0 cough remedies

bronchodilators 7eu&otriene antagonist

Mechanism of action: It bloc&s the binding of some leu&otrienes to cells that cause inflammation#

6ecrease severity of acute asthma and allergic rhinitis. Why is THIS pt taking? Patient ta&ing it for asthma and allergic rhinitis Monitoring parameters: assess lung sounds and res%iratory function %rior to and %eriodically during thera%y# assess allergy sym%toms )rhinitis con4unctivitis hives, before and %eriodically monitor closely for changes in behavior that could indicate the emergence or "orsening of de%ression or suicidal thoughts. Pt teaching side effects: instruct %atient to ta&e medication daily in the evening even if not e/%eriencing sym%toms of asthma. 6o not double doses discontinue thera%y "ithout consulting %rovider it is not used to treat acute asthma attac&s but may be continued during an acute e/acerbation. Patient should carry ra%id(acting thera%y for bronchos%asm at all times. Side #ffects: suicidal thoughts agitation aggression an/iety de%ression disorientation headache fatigue insomnia irritability "ea&ness rash eosino%hilic conditions including 1hurg(2trauss syndrome fever. Drug: modafinil9Provigil Classification: central nervous system stimulants

Mechanism of action: %roduces 1N2 stimulation# Im%roves "a&efulness in %atients "ith e/cessive

daytime dro"siness due to narcole%sy 0 obstructive slee% a%nea. Why is THIS pt taking? Pt is slee%y and needs to be stimulated to stay a"a&e during the day Monitoring parameters: observe and document fre>uency of narcole%tic e%isodes )brain disorder involving %oor control of slee%("a&e(cycles, monitor for s.s of angioedema or ana%hyla/is )s"elling on face, elevated liver enzymes and changes in behavior that "ould indicate the emergence or "orsening of suicidal thoughts or de%ression assess for rash %eriodically during thera%y and discontinue if severe or accom%anied "ith fever general malaise fatigue muscle or 4oint aches oral lesions blisters con4unctivitis he%atitis and or eosino%hilia occurs. Pt teaching side effects: Instruct %atient to ta&e medication as directed# medication may im%air 4udgment encourage %atient and family to be alert for emergence of an/iety agitation %anic attac&s insomnia irritability hostility im%ulsivity hy%omania mania "orsening of de%ression and suicidal ideation# assess s.s on a day to day basis as changes may be abru%t and notify %rovider if rash or sym%toms of ana%hyla/is occur. Side #ffects: suicidal ideation headache aggression amnesia an/iety cata%le/y confusion delusion de%ression dizziness hallucinations insomnia seizures rhinitis e%ista/is %haryngitis dys%nea lung disorder arrhythmias chest %ain hy%ertension hy%otension

synco%e vasodilation increase liver enzymes nausea anore/ia mouth ulcers thirst vomiting urinary retention hy%erglycemia nec& %ain tremor and infection. Drug: pento'ifylline $Trental& Classification: anti%latelet

Mechanism of action: !ound to erythrocyte membrane# it inhibits %hos%hodiesterase resultanting in the

increase in cyclic A-P in red blood cells reduces blood viscosity due to decreased %lasma fibrinogen concentrations and inhibition of red blood cell and %latelet aggregation. Why is THIS pt taking? Aor treatment of intermittent claudication caused by %eri%heral artery diseas e 0 %romoting healing of stasis ulcers associated "ith venous insufficiency Monitoring parameters: monitor 5eart beat if fast heartbeat and c.o chest %ain call %rovider immediately. Pt teaching side effects: 6o not ta&e double dose# ta&e %ento/ifylline "ith meals to %revent u%set stomach. 1ommon adverse effects include nausea vomiting dizziness headache diarrhea blurred vision agitation insomnia and dro"siness. Rarely %atients may e/%erience abnormal heartbeats

elevation of liver function test 4aundice and he%atitis.
Drug: ampicillin $Sul,actam& inhibitors Classification: anti(infectives# amino%enicillin.beta lactamase

Mechanism of action: binds to bacterial cell "all resulting in cell death# bactericidal action.

Why is THIS pt taking? Patient is ta&ing it for %ro%hyla/is for s&in structure infection r.t surgery# soft tissues intra(abdominal res%iratory 0 'I infection. Monitoring parameters: Assess %atient for infection )vital signs "ound a%%earance s%utum urine stool and N!1s, at beginning and throughout thera%y# -onitor A2$ A7$ 765 bilirubin al&aline %hos%hatase !UN and creatinine. Pt teaching side effects: Advice %atient to re%ort signs of su%er infection )furry overgro"th on the tongue foul smelling stools and allergy. Side #ffects: seizures %seudomembranous colitis diarrhea n.v rashes urticarial blood dyscrasias %ain at I- site %ain at I3 site allergic reactions including ana%hyla/is and serum sic&ness su%er(infection elevated liver enzymes. Drug: hydromorphone $Dilaudid& agonist Classification: opioid analgesics )antitussives, o%ioid

Mechanism of action: binds to o%iate rece%tors in the 1N2. Alters the %erce%tion of and res%onse to

%ainful stimuli "hile %roducing generalized 1N2 de%ression# su%%resses the cough refle/ via a direct central action. Why is THIS pt taking? $he decrease in moderate to severe %ain 0 su%%ression of cough Monitoring parameters: Assess !P Pulse 0 res%irations before and %eriodically during administration #

assess ty%e location and intensity of %ain %rior to and = hr. after PO or ? mins after I3 administration.
Pt teaching side effects: Instruct %atient on ho" and "hen to as& for %ain medication# change %ositions slo"ly to minimize orthostatic hy%otension encourage %atient to turn cough and breathe dee%ly every

t"o hours to %revent atelectasis. 2ide effects: confusion sedation dizziness dys%horia eu%horia floating feeling hallucinations headache blurred vision res%iration de%ression hy%otension and consti%ation. Drug: le-oflo.acin $/e-a0uin& Classification: anti(infectives# fluoro>uinolones

Mechanism of action: Inhibits bacterial 6NA synthesis by inhibiting 6NA gyrase: 6eath of susce%tible

bacteria broad activity includes many gramI %athogens. Why is THIS pt taking? Aor s&in and s&in structure infection r.t surgery other: res%. tract bone and 4oint infection. Monitoring parameters: assess for infection )vital signs a%%earance of "ound s%utum urine and stool# N!1 urinalysis fre>uency and urgency of urination cloudy or foul smelling urine and %rior and during thera%y. Obtain s%ecimens for culture and sensitivity before initiating thera%y. -onitor !o"el function diarrhea abdominal cram%ing fever bloody stools should be re%orted to %hysician %rom%tly as a sign of 1. diff. s.s of ana%hyla/is )rash "heezing laryngeal edema, &ee% e%ine%hrine and antihistamine close by in case of ana%hylactic e%isode. Pt teaching side effects: Instruct the %atient to ta&e medications as directed at evenly s%aced times and to finish drug com%letely even "hen feeling better do not double dose notify %rovider if ta&ing theo%hylline advise %t. that antacids or med containing iron or zinc "ill decrease absor%tion. Notify %rovidr if C$ %rolongation or %roarrhythmic conditions such as recent hy%o&alemia significant bradycardia or recent -I or fainting s%ells or %al%itations occur. Notify %rovider if su%er infection )furry overgro"th on tongue foul smelling stool occurs. As "ell as rashes 4aundice %ain s"elling occurs. Side effects: elevated intracranial %ressure seizure dizziness headache insomnia acute %sychoses agitation confusion de%ression dro"siness tremor C$ %rologation vasodilation he%atoto/ity diarrhea nausea abdominal %ain increase liver enzymes hy%oglycemia %hlebitis at I3 site tendinitis hy%ersensitivity reactions. Drug: Clopidogrel Pla-i. inhibitor Classification: anti%latelet agent %latelet aggregation

Mechanism of action: inhibits %latelet aggregation by irreversibly inhibiting the binding of A$P to %latelet

rece%tors. Why is THIS pt taking? Reduction of atherosclerotic events r.t -I acute coronary syndrome unstable angina stro&e and P36 Monitoring parameters: assess %atient for sym%toms of stro&e P36 -I %eriodically during thera%y. -onitor for signs of thrombocyto%enia neurologic findings fever etc. 7ab test: bleeding time during thera%y# 1!1 "ith differential and %latelet count %eriodically# -ay cause increase of bilirubin he%atic enzymes total cholesterol non%rotein nitrogen and uric acid concentrations. Pt teaching side effects: advise %atient to notify %rovider %rom%tly if fever chills sore throat or unusual bleeding or bruising occurs also any R/ or O$1 medications herbal vitamins %roducts ta&en ! Side effects: de%ression dizziness fatigue headache e%ista/is cough dys%nea chest %ain edema hy%ertension bleeding abdominal %ain diarrhea dys%e%sia gastritis %ruritis %ur%ura rash neutro%enia thrombotic thrombocyto%enic %ur%ura hy%ercholesterolemia arthralgia bac& %ain fever hy%ersensitivity reaction.

Drug: Bylo%rim.allo%urinol

Classification: Anti(gout agents antihy%er(uricemics

Mechanism of action: Inhibits %roduction of uric acid by inhibiting the action of /anthine o/idase. Why is THIS pt taking?: Prevention of attac& of gouty arthritis# to %revent ne%hro%athy. Monitoring parameters: I.O(+idney failure monitor 4oint for %ain and s"elling !2 Pt teaching side effects: 6rin& lots of fluid "ith %ill ta&e "ith a meal may be crushed if cannot s"allo" "hole. rash hy%otension bradycardia diarrhea flushing and dro"siness.

-ore meds.-egan
Drug: 7i%itor.atorvastatin Classification: li%id(lo"ering agents

Mechanism of action: Inhibit the enzyme 5-'(1oA reductase that is res%onsible for catalyzing an early ste% in the synthesis of cholesterol. Why is THIS pt taking?: 5as multi%le ris& factors for coronary heart disease. Monitoring parameters: *valuate cholesterol and triglyceride levels monitor liver function test muscle tenderness and 1+ levels. Pt teaching side effects: Notify us if une/%lained muscle %ain tenderness or "ea&ness occurs es%ecially "ith fever.abdominal cram%s consti%ation diarrhea flatus heartburn rashes. Drug: Rocaltrol.calcitriol Classification: fat(souble vitamins

Mechanism of action: Promotes the absor%tion of 1aI 0 decreased %arathyroid hormone concentrations Why is THIS pt taking?: Prevention or treatment of secondary hy%er%arathyroidism for 1+6. Monitoring parameters: Assess for bone %ain 0 "ea&ness hy%ercalcemia hy%er%hos%hatemia. Pt teaching side effects: 6o not e/ceed R6A avoid concurrent use for antacids containing magnesium. 6izziness malaise dys%nea. Drug: car-edilol )Coreg& Classification: antihy%ertensives.beta bloc&er

Mechanism of action: !loc&s stimulation of beta= and beta @ rece%tor sites. It decreases heart rate and !P. Im%roved cardiac out%ut slo"s the %rogression of 5A and decreased ris& of death. Why is THIS pt taking? Patient has 15A and hy%ertension. Monitoring parameters: -onitor !P 5R I.Os 0 daily "eights along "ith !2. . 1hec& %ulse and !P before ta&ing the medication hold meds if 5R P<; or systolic P=;; . 6izziness fatigue "ea&ness erectile dysfunction diarrhea. Pt teaching side effects: Instruct %atient to ta&e medication as directed abru%t "ithdra"al may %reci%itate life(threatening arrhythmias hy%ertension or myocardial ischemia. Patient should change %ositions slo"ly to minimize orthostatic hy%otension

Drug: Neurotin.gaba%entin

Classification: analgesic ad4uncts mood stabilizer thera%eutic anti(convulsant

Mechanism of action: not &no"n may affect trans%ort of amino acid across and stabilze neuronal membranes

Drug: Ativan.loraze%am

Classification: anesthetic ad4uncts anti(an/iety agents sedative. hy%notic

Mechanism of action: 6e%resses the 1N2 %otentiating 'A!A Why is THIS pt taking?: Restlessness and to hel% him slee%. Monitoring parameters: 1N2 reactions an/iety and s Why is THIS pt taking?: Used to relieve neuro%athic %ain Monitoring parameters: 1hanges in behavior seizures %ain )location intensity ty%e, Pt teaching side effects: 6o not ta&e med "ithin @ hours of ta&ing antacid. Notify 51P if thoughts of suicide or an/iety "orsen. 1onfusion ata/ia de%ression 0 dro"siness. Pt teaching side effects: $a%er off of the med to decrease "ithdra"al sym%toms avoid *$O5 "hile ta&ing the med. 6izziness dro"siness and lethargy. Drug: citalo%ram )1ele/a, Classification: antide%ressants . selective serotonin reu%ta&e inhibitors )22RIs,

Mechanism of action: Antide%ressant action. Why is THIS pt taking?: 6e%ression Monitoring parameters: Assess for suicidal tendencies es%ecially during early thera%y and dose changes. Assess for serotonin syndrome. -onitor mood changes during thera%y. Pt teaching side effects: Instruct %atient to ta&e medication as directed. 1aution %atient to change %ositions slo"ly to minimize dizziness. Advise %atient family and caregivers to loo& for suicidality es%ecially during early thera%y or dose changes. Notify the healthcare %rovider for the follo"ing adverse effects: neurole%tic malignant syndrome suicidal thoughts a%athy confusion dro"siness insomnia "ea&ness abdominal %ain anore/ia diarrhea dry mouth dys%e%sia flatulence increased saliva nausea s"eating and tremor.

Drug: 1ytotec.miso%rostol

Classification: antiulcer agents

Mechanism of action: Acts as %rostaglandin analogue decreasing gastric acid secretion and increase %roduction of %rotective mucus. Why is THIS pt taking?: Patient is diagnosed "ith '*R6 Monitoring parameters: Assess for e%igastric or abdominal %ain and for fran& or occult blood in stool emesis or gastric as%irate.

Pt teaching side effects: 6o not share may cause diarrhea avoid alcohol and foods that may increase 'I irritation "hile ta&ing the med.abdominal %ain and diarrhea. Drug: Protoni/.%anto%razole Classification: anti(ulcer agents

Mechanism of action: !inds to enzyme in the %resence of acidic gastric %5 %reventing the final trans%ort of 5I into gastric lumen# Proton(%um% inhibitor. Why is THIS pt taking?: $o treat his '*R6. Monitoring parameters: -onitor for e%igastric and abdominal %ain fran& or occult blood and s.s of hy%omagnesemia Pt teaching side effects: $a&e medication as directed for the full course of thera%y even if feeling better. Advise to avoid alcohol %roducts containing as%irin or N2AI6s 0 foods that may cause an increase in 'I irritation. Re%ort onset of blac& tarry stools diarrhea or abdominal %ain.headache abdominal %ain diarrhea flatulence. Drug: 3ancocin.vancomycin Classification: Anti infective

Mechanism of action: !inds to bacterial cell "all destroying the "all resulting in cell death. Why is THIS pt taking?: $a&ing to treat 1lostridium difficile Monitoring parameters: Assess %atient for infection !P es%ecially stool I.Os "eight and s.s of su%er( infection. Pt teaching side effects: $a&e as directed ta&e missed dose as soon as remembered unless close to loss.ne%hroto/icity ototo/icity hy%otension nausea vomiting and %hlebitis.

Drug: 1oumadin."arfarin

Classification: anticoagulant

Mechanism of action: Interferes "ith he%atic synthesis of vitamin + de%endent clotting factors. Why is THIS pt taking?: $he %atient has atrial fibrillation "hich %uts him at ris& for blood clots so this hel%s thin the blood and %revent clots. Monitoring parameters: -onitor P$.INR: If above :.; hold. Assess for signs of bleeding and hemorrhage. Assess for evidence of additional or increased thrombosis. Pt teaching side effects: Instruct %atient to ta&e medication as directed. 6o not double dose. Revie" foods high in vitamin +. *ducate that they should have consistent limited inta&e of these foods as vitamin + is the antidote for "arfarin. Re%ort any sym%toms of unusual bleeding or bruising. Instruct %atient not to drin& alcohol or ta&e other RG O$1 or herbal %roducts es%ecially those containing as%irin or N2AI6s or to start or sto% any ne" medication during "arfarin thera%y "ithout advice of 51P. *m%hasize the im%ortance of fre>uent lab test to monitor coagulation factors.cram%s nausea dermal necrosis bleeding and fever. Drug: allo%urinol )Alo%rim, Classification: $hera%eutic: antigout agents antihy%eruricemics Pharmacologic: /anthine o/idase inhibitors

Mechanism of action: Inhibits the %roduction of uric acid by inhibiting the action of /anthine o/idase. $hera%eutic *ffects: 7o"ering of serum uric acid levels. Why is THIS pt taking?: Prevention of attac& of gouty arthritis and ne%hro%athy )&idney disease,. PO I3: $reatment of secondary hy%eruricemia )high level of uric acid in the blood, "hich may occur during treatment of tumors or leu&emias. Monitoring parameters: -onitor I.O ratios. 6ecreased &idney function can cause drug accumulation and to/ic effects. Assess %atient for rash or more severe hy%ersensitivity reactions. -onitor for 4oint %ain and s"elling from gout. 7abs: 2erum and urine uric acid levels usually begin decrease @M: days after PO thera%y. -onitor blood glucose in %atients receiving oral hy%oglycemic agents. -ay cause hy%oglycemia. -onitor hematologic renal and liver function tests before and %eriodically during thera%y. -ay cause serum al&aline %hos%hatase bilirubin A2$ and A7$ levels. 1!1 and %latelets may indicate bone marro" de%ression. !UN serum creatinine may indicate ne%hroto/icity. Pt teaching side effects: Instruct %atient to ta&e as instructed increase fluids be a"are of side effects and follo" u% on e/ams. 2ide *ffects: dro"siness diarrhea nausea vomiting and rash.

Drug: e%oetin. *%ogen

Classification: antianemics hormones

Mechanism of action: 2timulates erythro%oiesis. Why is THIS pt taking?: 5as anemia related to her end stage renal failure her &idneys are not e/creting erythro%oietin. Monitoring parameters: -onitor !P during and after thera%y monitor for s.s of anemia )fatigue dys%nea %allor., -onitor dialysis shunts )thrill and bruit,. -onitor hemoglobin and hematocrit before and t"ice "ee&ly during intial thera%y. -onitor 1!1 "ith differential and %latelet count, If hemoglobin increase above ==g.d7 reduce dose by @?K and if continued increase hold. -onitor 'AR and electrolytes. Pt teaching side effects: Advise %t. to read the -edication 'uide %rior to initiation thera%y and "ith each R/ refill in case of changes. */%lain rationale for concurrent iron thera%y. 6iscuss "ays of %reventing self(in4ury in %atients at ris& for seizures. 6riving and activities re>uiring continuous alertness should be avoided. Advise %atient to notify 51P immediately if signs of blood clots )chest %ain trouble breathing or shortness of breath %ain in the legs etc.., occurs. 2tress im%ortance of com%liance "ith dietary restrictions medications and dialysis. Aoods high in iron and lo" in %otassium should be discussed. 2hould be taught %ro%er dosage administration techni>ue and di%osal of e>ui%ment. hy%ertension increased mortality and increased tumor gro"th seizures headache 15A -I 2tro&e thromboembolic events. Drug: letrozole.Aemara Classification: antineo%lastics aromatase inhibitors

Mechanism of action: Inhibits the enzyme aromatase "hich is %artially res%onsible for conversion of %recursors to estrogen. Why is THIS pt taking?: Nas diagnosed "ith !reast cancer in @;;Q trying to &ee% estrogen levels do"n. Monitoring parameters: Assess %atient for %ain and other side effects %eriodically throughout thera%y.

-onitor A2$ A7$ al&aline %hos%hatase bilirubin ''$ and cholesterol levels. Pt teaching side effects: Instruct %atient to ta&e medication as directed. 1aution %t to avoid driving and other activities re>uiring a"areness until res%onse to mediation is &no"n. Inform %atient of %otential for adverse reactions and advise her to notify health care %rofessional if side effects are %roblematic..An/iety de%ression dizziness dro"siness nausea musculos&eletal %ain. Drug: levothyro/ine.2ynthroid Classification: hormones thyroid %re%arations

Mechanism of action: Re%lacement of or su%%lementation to endogenous thyroid hormones. Princi%le effect is increasing metabolic rate of body tissues. Why is THIS pt taking?: Patient has hy%othyroidism Monitoring parameters: Assess a%ical %ulse and !P %rior to and %eriodically during thera%y. Assess for tachyarrhythmias and chest %ain. -onitor thyroid function $25 serum levels monitor blood and urine glucose in diabetics. Pt teaching side effects: Instruct %atient to ta&e medication as directed at the same time each day. */%lain to %atient that mediation does not cure hy%othyroidism %rovides thyroid hormone su%%lement. Notify 51P if headache nervousness diarrhea e/cessive s"eating heat intolerance chest %ain tachycardia %al%itations or "eight loss occur..headache insomnia irritability s"eating arrhythmias diarrhea vomiting angina %ectoris. Drug: ome%razole )Prilosec( %egerid& Classification: antiulcer agents %roton(%um% inhibitors

Mechanism of action: !inds to an enzyme on gastric %arietal cells in the %resence of acidic gastric %5 %reventing the final trans%ort of hydrogen ions into the gastric lumen. Why is THIS pt taking?: Acid reflu/ 0 relief '*R6 Monitoring parameters: Administer does before meals %referably in the morning must be s"allo"ed "hole. . -onitor 1!1 "ith differential %eriodically during thera%y. -onitor INR and %rothrombin time in %tLs ta&ing "arfarin. -onitor serum magnesium %rior to and %eriodically during thera%y. Assess for e%igastric or abd. Pain# and fran& blood in stools emesis or gastric as%irate. Pt teaching side effects: $a&e in the morning before brea&fast do not crush s"allo" "hole. $a&e for the full course thera%y even if feeling better. Advise to avoid alcohol %roducts containing as%irin or N2AI6s and food that may cause increase in 'I irritation. Re%ort onset of blac& tarry stools# diarrhea# abdominal %ain# or or %ersistent headache to 51P..dizziness dro"siness fatigue headache "ea&ness chest %ain abdominal %ain consti%ation diarrhea flatulence nausea vomiting. Drug: sevelamer )Renvela Renegel, Classification: electrolyte modifiers %hos%hate binders

Mechanism of action: A %olymer that binds %hos%hate in the 'I tract %reventing its absor%tion. Why is THIS pt taking?: 2he has end stage renal disease the &idney has an inability to e/crete the %hos%hate. Monitoring parameters: Assess %atient for 'I side effects %eriodically during thera%y. -onitor serum %hos%horous calcium bicarbonate and chloride levels %eriodically during thera%y.

Pt teaching side effects: Instruct %atient to ta&e sevelamer "ith meals as directed and to adhere to %rescribed dies. 1aution %atient to s%ace concurrent medications at least = hr before or : hr after sevelamer. Advise %atient to notify 51P if 'I effects are sever or %rolonged. Drug: ceftazidime.Aortaz Classification: anti(infectives third(gneration ce%halos%orins

Mechanism of action: !ind to the bacterial cell "all membrane causing cell death. Why is THIS pt taking?: $a&ing to treat 1elulitis Monitoring parameters: Assess for infection: 32 Observe for s.s of ana%hyla/is monitor bo"el function. Pt teaching side effects: Instruct %atient to ta&e mediation arund the cloc& and to finish the medication com%letely even if feeling better. Instruct %atients that concurrent use of alcohol "ith cefo%erazone may cause a disulfiram li&e reaction. Notify health care %rofessional if rash fever and diarrhea develo%. Drug: atenolol. $enormin Classification: antianginals antihy%ertensives beta bloc&ers

Mechanism of action: !loc&s stimulation of beta= rece%tors. Why is THIS pt taking?: tachycardia and hy%ertension Monitoring parameters: 3itals es%ecially 5R and !P and *1' I.Os daily "eights assess routinely for 5A angina. Pt teaching side effects: $a&e as directed at the same time each day even if feeling "ell# do not s&% or double u% on missed doses. $each %atient and family ho" to chec& %ulse and !P. 1hange %ositions slo"ly to minimize orthostatic hy%otension. Notify 51P of a ll R/ or O$1 meds vitamins or herbal %roducts being ta&en avoid alcohol. Advise %atient to notify 1P if slo" %ulse difficulty breathing "heezing cold hands and feet dizziness lightheadedness confusion de%ression rash feer sore throat unusual bleeding or bruising occurs.

Arom 7eslie
Drug: amlodi%ine $+or-asc& Classification: antihy%ertensives . calcium channel bloc&ers

Mechanism of action: 2ystemic vasodilation resulting in decreased !P. 1oronary vasodilation resulting in decreased fre>uency and severity of attac&s of angina. Why is THIS pt taking?: Patient has hy%ertension. Monitoring parameters: -onitor !P and %ulse before thera%y during dose titration and %eriodically during thera%y. -onitor *1' %eriodically. -onitor inta&e and out%ut ratios and daily "eight. Pt teaching side effects: Advise %atient to ta&e medication as directed to change %ositions slo"ly to minimize orthostatic hy%otension notify health %rofessional if any of the follo"ing adverse effects occur: headache dizziness fatigue %eri%heral edema angina bradycardia hy%otension %al%itations gingival hy%er%lasia nausea and flushing Drug: 2odium bicarbonate $anti1acid& Classification: antiulcer agents . al&alinizing agents

Mechanism of action: Al&alinization. Neutralization of gastricacid.

Why is THIS pt taking?: $o &ee% the %5 from getting too acidic. Monitoring parameters: Assess %atients for signs of acidosis )disorientation headache "ea&ness dys%nea and hy%erventilation, and al&alosis )confusion irritability %aresthesia tetany and altered breathing %attern,. Pt teaching side effects: Instruct %atient to ta&e medication as directed. Advise %atient not to ta&e mil& %roducts concurrently "ith this medication. Revie" sym%toms of electrolyte imbalance "ith %atients "ith this medication. Notify the healthcare %rovider is the follo"ing adverse effects occur: metabolic al&alosis edema flatulence gastric distention hy%ernatremia hy%ocalcemia and hy%o&alemia. Drug: Novolog insulin aspart Classification: antidiabetics hormones . %ancreatics

Mechanism of action: 1ontrol of hy%erglycemia in diabetic %atients. Why is THIS pt taking? Patient has diabetes mellitus. Monitoring parameters: Assess for sym%toms of hy%oglycemia. -onitor body "eight %eriodically. Assess %atient for signs of allergic reactions during thera%y. Pt teaching side effects: Instruct %atient on %ro%er techni>ue for administration. */%lain to %atient tha the medication controls hy%erglycemia but does not cure diabetes. Instruct %atient in %ro%er testing of serum glucose and &etones. Instruct %atient on sym%toms and signs of hy%oglycemia. Notify healthcare %rovider if the follo"ing adverse effects occur: hy%oglycemia erythema li%odystro%hy %ruritis s"elling allergic reactions including ana%hyla/is. Drug: sodium chloride Classification: -ineral and electrolyte re%lacement.su%%lements

Mechanism of action: Re%lacement in deficiency states and maintenance of homeostasis. Why is THIS pt taking?: 2cheduled to flush I3 line. Monitoring parameters: Assess fluid balance )inta&es and out%ut daily "eight edema lung sounds, throughout thera%y. Assess %atient for sym%toms of hy%onatremia )headache tachycardia lassitude dry mucous membranes,. Pt teaching side effects: */%lain to %atient %ur%ose of the infusion. 1ontact healthcare %rofessional for the follo"ing adverse effects: 5A %ulmonary edema edema hy%ernatremia hy%ervolemia e/travasation and irritation at I3 site. Drug: glucagon Classification: hormones . %ancreatics

Mechanism of action: Increase in blood glucose. Rela/ation of 'I musculature facilitating radiogra%hic e/amination. Why is THIS pt taking?: $o treat hy%oglycemia. Monitoring parameters: Assess for signs of hy%oglycemia %rior to and %eriodically during thera%y. Assess neurologic status throughout thera%y. Assess nutritional status. Assess for nausea and vomiting after administration of dose. Pt teaching side effects: $each %atient and family signs and sym%toms of hy%oglycemia. Notify the healthcare %rovider if the follo"ing adverse effects occur: hy%otension nausea vomiting hy%ersensitivity

reactions including ana%hyla/is. Drug: o/ycodone Classification: o%ioid analgesics . o%ioid agonists o%ioid agonists.nono%ioid analgesic combinations

Mechanism of action: 6ecreased %ain. Why is THIS pt taking?: Pain. Monitoring parameters: Assess ty%e location and intensity of %ain %rior to and = hr )%ea&, after administration. Assess !P %ulse and res%irations before and %eriodically during administration. Assess bo"el function routinely. Pt teaching side effects: Instruct %atient on ho" and "hen to as& for and ta&e %ain medication. Advise %atient that o/ycodone is a drug "ith &no"n abuse %otential. Advise %atient to ma&e %osition changes slo"ly to minimize orthostatic hy%otension. Notify healthcare %rofessional of the follo"ing adverse effects: confusion sedation consti%ation res%iratory de%ression. Drug: fentanyl M transdermal )6uragesic, Classification: o%ioid analgesics anesthetic ad4uncts . o%ioid agonists

Mechanism of action: 6ecrease in severity of chronic %ain. Why is THIS pt taking?: Pain. Monitoring parameters: Assess ty%e location and intensity of %ain before and @D hr after a%%lication and %eriodically during thera%y. Assess !P %ulse and res%iration before and %eriodically during administration. Prolonged use may lead to %hysical and %sychological de%endence and tolerance. Progressively higher doses may be re>uired to relieve %ain "ith long(term thera%y. Assess bo"el function routinely. Pt teaching side effects: Instruct %atient in ho" and "hen to as& for and ta&e %ain medication. Instruct %atient incorrect method for a%%lication and dis%osal of transdermal system. Advise %atient to change %ositions slo"ly to minimize dizziness. 1aution %atient to avoid concurrent use of alcohol or other 1N2 de%ressants "ith this medication. Notify healthcare %rovider of the follo"ing adverse effects: confusion sedation "ea&ness anore/ia consti%ation dry mouth nausea vomiting and s"eating. Drug: ferrous sulfate )2eosol( 2erata,( 2e34& Classification: anti(anemic.iron su%%lements

Mechanism of action: Prevention.treatment of iron deficiency. Why is THIS pt taking?: Patient has anemia. Monitoring parameters: Assess nutritional status and dietary history to determine %ossible cause of anemia and need for %atient teaching. Assess bo"el functions for consti%ation or diarrhea. Assess %atient for signs and sym%toms of ana%hyla/is )rash %ruritus laryngeal edema "heezing, for at least :; minutes. -onitor hemoglobin hematocrit 0 reticulocyte values %rior to and every : "&s during the first @mo of thera%y and %eriodically thereafter. Pt teaching side effects: */%lain %ur%ose of iron thera%y to %atient. *ncourage %atient to com%ly "ith medication regimen. Advise %atient that stools may become dar& green or blac& and that this change is harmless. Instruct %atient to follo" a diet high in iron. Notify healthcare %rovider of the follo"ing adverse

effects: seizures ana%hyla/is hy%otension nausea consti%ation dar& stools diarrhea and e%igastric %ain. Drug: fludrocortisone )Alorinef, Classification: hormones . corticosteroids )mineralocorticoid,

Mechanism of action: -aintenance of sodium balance and !P in %atients "ith adrenocortical insufficiency. Why is THIS pt taking?: Patient has &idney failure. Monitoring parameters: -onitor !P %eriodically during thera%y. -onitor fluid retention. 1auses decrease in serum %otassium levels. Pt teaching side effects: Instruct %atient to ta&e medication as directed. Advise %atient to follo" dietary modifications %rescribed by healthcare %rofessional. Notify healthcare %rovider of the follo"ing adverse effects: dizziness headache arrhythmias edema hy%ertension anore/ia nausea "eight gain hy%o&alemia hy%o&alemic al&alosis and hy%ersensitivity reactions. Drug: mero%enem )-errem, Classification: anti(infectives. 1arba%enems are a class of R(lactam antibiotics "ith a broad s%ectrum of antibacterial activity. Mechanism of action: !actericidal action against susce%tible bacteria. Why is THIS pt taking?: Patient has a bacterial U$I. Monitoring parameters: Assess infection at beginning of and throughout thera%y. Obtain a history before initiating thera%y to determine %revious use of and reactions to %enicillins# Observe for signs and sym%toms of ana%hyla/is. !UN A2$ A7$ 765 serum al&aline %hos%hatase bilirubin and creatinine may be transiently increased. Pt teaching side effects: Advise %atient to re%ort the signs of su%er infection and allergy# -ay cause dizziness. Notify healthcare %rofessional for the follo"ing adverse effects: seizures a%nea dizziness diarrhea nausea vomiting and ana%hyla/is.

6rug: nystatin )-ycostatin Nysto%,

Classification: antifungals )to%ical,

Mechanism of action: 6ecrease in sym%toms of fungal infection. Why is THIS pt taking?: $o be a%%lied under the %atientSs folds to hel% "ith fungal infection. Monitoring parameters: Ins%ect involved areas of s&in and mucous membranes before and fre>uently during thera%y. Increased s&in irritation may indicate need to discontinue medication. Pt teaching side effects: Instruct %atient to a%%ly medication as directed for full course of thera%y even if feeling better. Advise %atient to re%ort increased s&in irritation or lac& of res%onse to thera%y to healthcare %rofessional. Notify healthcare %rofessional of the follo"ing adverse effects: burning itching local hy%ersensitivity reactions redness and stinging. 2ide effects: dizziness tachycardia sodium retention drug(induced lu%us syndrome dro"siness headache angina arrhythmias edema orthostatic hy%otension n.v %eri%heral neuro%athy.

6rug: 5ydralazine )A%resoline,

classification: antihy%ertensive.vasodilator

Mechanism of action: direct acting %eri%heral arteriolar vasodilator to lo"er !P in hy%ertensive %atients and decrease afterload in %atients "ith 5A. Why is this pt! taking? Aor moderate to severe 5y%ertension Monitoring parameters: monitor !P %ulse fre>uently )ethnic ris& of to/icity ie 1aucasians !lac& -e/ican slo" acetylators "hile Ha%anese 1hinese are ra%id acetylators at ris& for decreased levels and treatment failure,# labs: 1!1 electrolytes 7* cell %re% and ANA titer %rior to and %eriodically during %rolonged thera%y. Administer "ith meals consistently to enhance absor%tion. Pt! teaching side effects: *ncourage %atient to continue ta&ing medication on same time each day and even if feeling "ell. $o com%ly "ith additional interventions for hy%ertension )"eight reduction lo" sodium diet smo&ing cessation and moderation of alcohol inta&e e/ercise and stress management,# notify care %rovider of general tiredness fever muscle or numbness tingling %ain or "ea&ness of hands occurs and em%hasize im%ortance of follo" u% e/am to evaluate effectiveness of medication. Drug: fluo/etine )Prozac, Classification: $hera%eutic: antide%ressants Pharmacologic: selective serotonin reu%ta&e inhibitors )22RIs,

Mechanism of action: 2electively inhibits the reu%ta&e of serotonin in the 1N2. $hera%eutic *ffects: Antide%ressant action. 6ecreased behaviors associated "ith: %anic disorder bulimia. 6ecreased mood alterations associated "ith %remenstrual dys%horic disorder )P-66,. Why is THIS pt taking?: -ood enhancement. Monitoring parameters: -onitor mood changes. Assess for suicidal tendencies es%ecially during early thera%y. -onitor a%%etite and nutritional inta&e. Assess %atient for sensitivity reaction. Assess for se/ual side effects. Assess %atient for fre>uency of obsessive(com%ulsive behaviors. Note degree to "hich these thoughts and behaviors interfere "ith daily functioning. Assess fre>uency of binge eating and vomiting during thera%y. -onitor 1!1 and differential %eriodically during thera%y. Pt teaching side effects: It may ta&e u% to D "ee&s before the full effect occurs. $a&e in the morning. If you feel slee%y or tired you may ta&e it at night# If you are ta&ing the once("ee&ly ca%sule mar& calendar "ith reminders of drug day. 6o not ta&e this drug during %regnancy. If you thin& that you are %regnant or "ish to become %regnant consult your health care %rovider. +ee% this drug and all medications out of the reach of children. 2ide effects: 5eadache nervousness insomnia dro"siness an/iety tremor diarrhea se/ual dysfunction s"eating and %ruritus# life threatening: N*URO7*P$I1 -A7I'NAN$ 2YN6RO-* 2*IBUR*2 2UI1I6A7 $5OU'5$2 and 2*RO$ONIN 2YN6RO-*. Drug: isosorbide mononitrate )I-6UR, Classification: $hera%eutic: antianginals Pharmacologic: nitrates

Mechanism of action: Produce vasodilation )venous greater than arterial,. 6ecrease left ventricular end( diastolic %ressure and left ventricular end(diastolic volume )%reload,. Net effect is reduced myocardial o/ygen consum%tion. Increase coronary blood flo" by dilating coronary arteries and im%roving collateral flo" to ischemic regions. $hera%eutic *ffects: Angina ( relieve and %revention. Increase cardiac out%ut. Why is THIS pt taking?: Relief of angina. Monitoring parameters: Assess location duration intensity and %reci%itating factors of anginal %ain. -onitor !P and P routinely during %eriod of dosage ad4ustment.

Pt teaching side effects: $a&e as directed. Ris& of orthostatic hy%otension# -ay cause dizziness# 6riving caution. Avoid alcohol# O$1 herbal su%%l. revie" "ith 51P. 5eadache is a common side effect. A2A or acetamino%hen may be ordered to treat headache. Inform 51P if dry mouth or blurred vision occurs# side effects: dizziness headache a%%rehension restlessness "ea&ness blurred vision hy%otension tachycardia synco%e abd %ain N.3 flushing and tolerance

Sponsor Documents

Or use your account on DocShare.tips

Hide

Forgot your password?

Or register your new account on DocShare.tips

Hide

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close